NCT01028638View on ClinicalTrials.gov

Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Metastatic Renal Cell Carcinoma
Interventions
OTHER

89Zr-bevacizumab PET scan

"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."

Trial Locations (1)

9700 RB

University Medical Centre Groningen, Groningen

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Medical Center Groningen

OTHER